Clinical trial
A Double-Blind, Placebo-Controlled Study of Caplyta in the Treatment of Borderline Personality Disorder
NCT05356013 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-Blind, Placebo-Controlled Study of Caplyta in the Treatment of Borderline Personality Disorder
- Lead sponsor
- University of Chicago
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 10, 2023
- Completion date
- December 31, 2025
- Enrollment
- 60 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.